You are here: Industry Insights > Market News > Indoco launches favipiravir 400 mg tablets

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

TAYACN Drying Ammonium thiocyanate ZLG series vibration fluidized bed dryer

TAYACN Drying Nickel chloride water ZLG series vibration fluidized bed dryer

TAYACN Drying Flavoring ZLG series vibration fluidized bed dryer

TAYACN Drying Resin ZLG series vibration fluidized bed dryer

TAYACN Drying Thiourea particles ZLG series vibration fluidized bed dryer

TAYACN Drying Sodium percarbonate ZLG series vibration fluidized bed dryer

Indoco launches favipiravir 400 mg tablets

expresspharmaSeptember 28, 2020

Tag: favipiravir , Indoco , COVID-19 , FEVINDO

Favorites

Indoco Remedies announced the launch of FEVINDO (favipiravir) 400 mg tablets in India. Fevindo – 400 is an antiviral drug, effective against the RNA-based influenza virus.

The drug has been approved by DCGI in the treatment of COVID-19.

Aditi Kare Panandikar, MD, Indoco Remedies commented, “With the launch of FEVINDO, we are taking the next step from prevention to the treatment of COVID-19.”

Fevindo – 400 will be made available at all government approved COVID care centres and selected medical practitioners across the country.

Previous:Happiness Biotech Announces $2.25 Million Private Placement In Support of Happy Buy

Next:Preventing counterfeiting with global identification standard

Alzheimer’s Disease: Charting the Course from Plaques to Promise

Muhammad Farhan KhalidMay 28, 2025

New Tools，New Hope，New Frontier

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

Indoco launches favipiravir 400 mg tablets | Pharmasources.com

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Telix Pharmaceuticals Limited announces that the pivotal Phase 3 registration study of TLX591-CDx for prostate cancer imaging in Chinese patients has completed patient enrolment.

free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

Indoco launches favipiravir 400 mg tablets

Related News

Alzheimer’s Disease: Charting the Course from Plaques to Promise

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

You may like
More>>

free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

Indoco launches favipiravir 400 mg tablets

Related News

Alzheimer’s Disease: Charting the Course from Plaques to Promise

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

You may likeMore>>

You may like
More>>